Research Analysts Offer Predictions for VIR Q2 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR) – Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Vir Biotechnology in a research note issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings per share of ($0.95) for the quarter. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.36) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s Q3 2025 earnings at ($0.88) EPS and Q4 2025 earnings at ($0.87) EPS.

VIR has been the subject of a number of other reports. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Leerink Partners upped their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a report on Friday. Barclays reduced their target price on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $20.00 in a research note on Thursday, January 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.83.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $10.52 on Tuesday. The business’s 50 day moving average price is $8.26 and its 200-day moving average price is $8.36. Vir Biotechnology has a 1 year low of $6.56 and a 1 year high of $14.45. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -2.68 and a beta of 0.51.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The business had revenue of $2.38 million for the quarter, compared to analysts’ expectations of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business’s revenue for the quarter was down 9.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.22) EPS.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of VIR. Millennium Management LLC grew its holdings in shares of Vir Biotechnology by 94.6% during the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock worth $11,108,000 after purchasing an additional 606,804 shares during the period. State Street Corp boosted its stake in Vir Biotechnology by 10.4% during the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock worth $42,135,000 after buying an additional 530,645 shares during the period. Federated Hermes Inc. increased its position in shares of Vir Biotechnology by 19,327.1% during the second quarter. Federated Hermes Inc. now owns 300,148 shares of the company’s stock valued at $2,671,000 after acquiring an additional 298,603 shares during the last quarter. Affinity Asset Advisors LLC purchased a new stake in shares of Vir Biotechnology in the 2nd quarter valued at approximately $1,780,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Vir Biotechnology by 6,402.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 188,624 shares of the company’s stock worth $1,679,000 after acquiring an additional 185,723 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Vicki L. Sato sold 10,960 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now owns 1,312,391 shares of the company’s stock, valued at approximately $16,431,135.32. This represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold 14,786 shares of company stock valued at $170,172 in the last ninety days. 15.60% of the stock is currently owned by corporate insiders.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).